A M Vannucchi

Summary

Affiliation: University of Florence
Country: Italy

Publications

  1. doi request reprint Advances in understanding and management of myeloproliferative neoplasms
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, Florence, Italy
    CA Cancer J Clin 59:171-91. 2009
  2. ncbi request reprint Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden
    A M Vannucchi
    Department of Hematology, University of Florence, Florence, Italy
    Leukemia 21:1952-9. 2007
  3. doi request reprint Treatment options for essential thrombocythemia and polycythemia vera
    Alessandro M Vannucchi
    UF di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Universita degli Studi, Viale Morgagni, Florence, Italy
    Expert Rev Hematol 2:41-55. 2009
  4. pmc From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
    Alessandro M Vannucchi
    CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Universita degli Studi, Firenze, DENOTHE Excellence Center, Italy
    Haematologica 102:18-29. 2017
  5. ncbi request reprint Thrombocytosis and thrombosis
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy
    Hematology Am Soc Hematol Educ Program . 2007
  6. pmc A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
    Alessandro M Vannucchi
    University of Florence, Italy
    Haematologica 100:1139-45. 2015
  7. pmc Chronic myeloproliferative neoplasms: a collaborative approach
    Lisa Pieri
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita degli Studi, Istituto Toscano Tumori, Firenze
    Mediterr J Hematol Infect Dis 2:e2010017. 2010
  8. pmc mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms
    Costanza Bogani
    Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
    PLoS ONE 8:e54826. 2013
  9. doi request reprint Mutations and prognosis in primary myelofibrosis
    A M Vannucchi
    Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
    Leukemia 27:1861-9. 2013
  10. doi request reprint JAK2 mutation-related disease and thrombosis
    Alessandro M Vannucchi
    Sezione di Ematologia, Dipartimento di Medicina Clinica e Sperimentale, Universita degli Studi di Firenze, Largo Brambilla 3, Florence, Italy
    Semin Thromb Hemost 39:496-506. 2013

Detail Information

Publications78

  1. doi request reprint Advances in understanding and management of myeloproliferative neoplasms
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, Florence, Italy
    CA Cancer J Clin 59:171-91. 2009
    ..In the current article, the authors provide a clinically oriented overview of MPNs in terms of their molecular pathogenesis, classification, diagnosis, and management...
  2. ncbi request reprint Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden
    A M Vannucchi
    Department of Hematology, University of Florence, Florence, Italy
    Leukemia 21:1952-9. 2007
    ..001) or developing major cardiovascular events (RR 7.1; P=0.003) during follow up were significantly increased. We conclude that a burden of JAK2(V617F) allele greater than 75% at diagnosis points to PV patients with high-risk disease...
  3. doi request reprint Treatment options for essential thrombocythemia and polycythemia vera
    Alessandro M Vannucchi
    UF di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Universita degli Studi, Viale Morgagni, Florence, Italy
    Expert Rev Hematol 2:41-55. 2009
    ..These different issues, and current recommendations for treatment, will be discussed in the review...
  4. pmc From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
    Alessandro M Vannucchi
    CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Universita degli Studi, Firenze, DENOTHE Excellence Center, Italy
    Haematologica 102:18-29. 2017
    ..This review will present a critical overview of evolving concepts in diagnosis and treatment of this disease...
  5. ncbi request reprint Thrombocytosis and thrombosis
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy
    Hematology Am Soc Hematol Educ Program . 2007
    ..Established and novel potential risk factors for thrombosis, including the clinical relevance of the JAK2V617F mutation, and current management strategies for thrombocytosis are also briefly discussed...
  6. pmc A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
    Alessandro M Vannucchi
    University of Florence, Italy
    Haematologica 100:1139-45. 2015
    ..clinicaltrials.gov identifiers: COMFORT-I, NCT00952289; COMFORT-II, NCT00934544). ..
  7. pmc Chronic myeloproliferative neoplasms: a collaborative approach
    Lisa Pieri
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita degli Studi, Istituto Toscano Tumori, Firenze
    Mediterr J Hematol Infect Dis 2:e2010017. 2010
    ..In this brief review, we will discuss some of the key issues that can arise along the clinical course of MPNs and require an integrated, strictly patient-oriented, approach...
  8. pmc mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms
    Costanza Bogani
    Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
    PLoS ONE 8:e54826. 2013
    ..The aim of the study was to characterize the effects in vitro of mTOR inhibitors, used alone and in combination with JAK2 inhibitors, against MPN cells...
  9. doi request reprint Mutations and prognosis in primary myelofibrosis
    A M Vannucchi
    Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
    Leukemia 27:1861-9. 2013
    ..Mutational profiling for ASXL1, EZH2, SRSF2 and IDH identifies PMF patients who are at risk for premature death or leukemic transformation...
  10. doi request reprint JAK2 mutation-related disease and thrombosis
    Alessandro M Vannucchi
    Sezione di Ematologia, Dipartimento di Medicina Clinica e Sperimentale, Universita degli Studi di Firenze, Largo Brambilla 3, Florence, Italy
    Semin Thromb Hemost 39:496-506. 2013
    ..In this review, we discuss about potential mechanisms that link mutated JAK2 with the thrombotic propensity of MPN and the clinical correlates; hopefully, novel information could result in better patient management...
  11. doi request reprint BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques
    Alessandro M Vannucchi
    Section of Hematology, Department of Critical Care, University of Florence, Largo Brambilla 3, 50134 Florence, Italy
    Future Oncol 8:575-93. 2012
    ..This review discusses how to manage, according to current clinical practice, the steps of diagnosis, prognostication and therapeutic choices in myeloproliferative neoplasm patients...
  12. doi request reprint How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis
    Alessandro M Vannucchi
    UF of Hematology, Department of Critical Care, University of Florence, Florence, Italy
    Leuk Res 33:1581-3. 2009
    ....
  13. ncbi request reprint Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, 50134 Florence, Italy
    Blood 110:840-6. 2007
    ..We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET...
  14. doi request reprint Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
    A M Vannucchi
    UF di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Universita degli Studi, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
    Leukemia 22:1299-307. 2008
    ....
  15. doi request reprint Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
    Alessandro M Vannucchi
    Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Universita degli Studi, Florence, Italy
    Blood 112:844-7. 2008
    ..These data indicate that MPLW515L/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart...
  16. ncbi request reprint A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis
    A M Vannucchi
    Department of Hematology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
    Leukemia 20:1055-60. 2006
    ..We propose that this method might complement current technologies based on genomic DNA analysis, and lead prospectively to a better clinically oriented assessment of the impact of JAK2(V617F) mutation in MPD...
  17. pmc Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
    Alessandro M Vannucchi
    UF di Ematologia, Dip Area Critica Medico Chirugica, Universita di Firenze, Firenze, Italy
    J Cell Mol Med 13:1437-50. 2009
    ..Novel basic and translational information concerning epigenetic gene regulation in MPNs and the perspectives for therapy will be critically addressed in this review...
  18. doi request reprint Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms
    Alessandro M Vannucchi
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita degli Studi di Firenze, Florence, Italy
    Cancer Epidemiol Biomarkers Prev 18:2068-73. 2009
    ..We conclude that the risk of developing LPN is significantly increased in MPN patients compared with the general population...
  19. pmc Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, Florence, Italy
    Am J Pathol 167:849-58. 2005
    ..We conclude that megakaryocytes from IM patients have reduced GATA-1 content, possibly contributing to disease pathogenesis as in the GATA-1(low) mice and also representing a novel IM-associated marker...
  20. doi request reprint Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia
    Alessandro M Vannucchi
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita degli Studi, Florence, Italy
    Intern Emerg Med 5:177-84. 2010
    ....
  21. doi request reprint JAK2 mutation and thrombosis in the myeloproliferative neoplasms
    Alessandro M Vannucchi
    Unita Funzionale di Ematologia, Universita degli Studi, Florence, Italy
    Curr Hematol Malig Rep 5:22-8. 2010
    ..It is hoped that elucidation of the role mutant JAK2 plays in MPNs will improve our understanding of the pathophysiology of thrombosis and eventually result in improved patient treatment using molecularly targeted drugs...
  22. doi request reprint Management of myelofibrosis
    Alessandro M Vannucchi
    Section of Hematology, Department of Critical Care, University of Florence, Florence, Italy
    Hematology Am Soc Hematol Educ Program 2011:222-30. 2011
    ..However, because these agents are all poorly effective in reducing the burden of mutated cells, further advancements are needed to move from enhancing our ability to palliate the disease to arriving at an actual cure for MF...
  23. ncbi request reprint An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia
    A Bosi
    Division of Hematology, University of Florence, Careggi Hospital, Italy
    J Chemother 11:287-92. 1999
    ..Death due to sepsis nor toxicity were observed. This triple antibiotic combination appears to be a very effective regimen for the empiric treatment of febrile episodes in severely neutropenic BMT recipients...
  24. ncbi request reprint Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice
    A M Vannucchi
    Division of Hematology, University of Florence and Azienda Ospedaliera Careggi, Florence, Italy
    Blood 95:2559-68. 2000
    ..TER-119(+)/4A5(+) cells represent a late bipotent erythroid and megakaryocytic cell precursors that may exert an important role in the recovery from PHZ-induced anemia. (Blood. 2000;95:2559-2568)..
  25. ncbi request reprint Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice)
    A M Vannucchi
    Department of Hematology and Istituto di Oncologia and Patologia Sperimentali, Istituto di Anatomia Patologica, University of Florence, Italy
    Blood 97:3040-50. 2001
    ..In conclusion, the GATA-1(low) mutation increases the magnitude of the response to erythroid stimuli as a consequence of the expansion of the erythroid progenitor cells in their spleen...
  26. ncbi request reprint Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients
    D Laszlo
    Bone Marrow Transplant Unit, University of Florence, Careggi Hospital, Florence, Italy
    J Chemother 9:95-101. 1997
    ..In conclusion, both Net + Imi and Net + Cef are active and safe as empirical treatment of febrile episodes in neutropenic BMT pts...
  27. pmc Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086
    C Cellai
    Department of Experimental Pathology and Oncology, School of Medicine, University of Florence, Viale G B Morgagni 50, 50134 Florence, Italy
    Br J Cancer 94:1637-42. 2006
    ..Overall, WEB-2086 can be proposed as an effective antiproliferative and differentiative agent with interesting translational opportunities to treat breast cancers in support to conventional chemotherapy...
  28. ncbi request reprint Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation
    C Nozzoli
    Department of Hematology, BMT Unit, University of Florence, Italy
    Leuk Lymphoma 47:167-9. 2006
    ....
  29. ncbi request reprint Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation
    V Santini
    Department of Hematology, University of Florence, Italy
    Haematologica 81:201-7. 1996
    ..Although the reverse transcriptase polymerase chain reaction (RT-PCR) method is largely employed, the clinical value and impact of a positive RT-PCR as a herald of hematological relapse has not yet been definitively ascertained...
  30. doi request reprint The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
    P Guglielmelli
    Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
    Leukemia 28:1804-10. 2014
    ..We conclude that the 'number' of prognostically detrimental mutations provides added value in the combined molecular and clinical prognostication of PMF...
  31. ncbi request reprint Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study
    A Bosi
    Bone Marrow Transplant Unit, Careggi Hospital, Florence, Italy
    J Chemother 5:191-6. 1993
    ..002), the absence of extrapyramidal reactions (p < 0.001) and no need for dose reduction (p < 0.001) as compared with patients treated with chlorpromazine...
  32. ncbi request reprint WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential
    A Laurenzana
    Department of Experimental Pathology and Oncology, University of Florence, Italy
    Leukemia 19:390-5. 2005
    ....
  33. pmc Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
    Alessandra Carobbio
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 112:3135-7. 2008
    ..These data challenge the theory that elevated platelet count increases thrombosis risk in ET and suggest prospective clinical trials to support this hypothesis...
  34. ncbi request reprint Aztreonam versus colistin-neomycin for selective decontamination of the digestive tract in patients undergoing bone marrow transplantation: a randomized study
    A Bosi
    Department of Hematology, University of Florence, Italy
    J Chemother 4:30-4. 1992
    ..No significant differences were observed suggesting that Az is at least as effective as the CN regimen and may be considered as an alternative approach for intestinal decontamination in BMT patients...
  35. ncbi request reprint Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia
    S Ciolli
    Department of Hematology, University and Hospital Careggi, 50139 Florence, Italy
    Leuk Lymphoma 45:73-8. 2004
    ..Thus, post-remission outcome highly depends on Flt3 status. Flt3 mutations identify patients at high risk of relapse, who should prospectively receive, according to age, either more aggressive or alternative therapeutic approaches...
  36. ncbi request reprint Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report
    G Gianfaldoni
    Department of Hematology, University of Florence, University Hospital Careggi, Florence, Italy
    J Chemother 17:449-51. 2005
    ..In conclusion, rituximab is a safe and effective alternative to other immunosuppressive therapies for chronic relapsing TTP patients...
  37. ncbi request reprint Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease
    Alessandro M Vannucchi
    Hematology Unit, University of Florence, AOC, Italy
    Semin Oncol 32:365-72. 2005
    ....
  38. ncbi request reprint Impaired GATA-1 expression and myelofibrosis in an animal model
    Alessandro M Vannucchi
    UF di Ematologia, Az Osp Careggi, University of Florence, 50134 Florence, Italy
    Pathol Biol (Paris) 52:275-9. 2004
    ....
  39. ncbi request reprint PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia
    Alessandro M Vannucchi
    Department of Haematology, University of Florence, Florence, Italy
    Br J Haematol 127:214-9. 2004
    ....
  40. ncbi request reprint Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma
    Alessandro M Vannucchi
    Department of Haematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    Br J Haematol 128:738. 2005
  41. doi request reprint Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
    Paola Guglielmelli
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita di Firenze, and Istituto Toscano Tumori, Firenze, Italy
    Blood 114:1477-83. 2009
    ....
  42. pmc A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction
    Alessandro Pancrazzi
    UF di Ematologia, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    J Mol Diagn 10:435-41. 2008
    ..It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy...
  43. pmc Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
    A M Vannucchi
    1 Department of Experimental and Clinical Medicine, Laboratorio Congiunto MMPC, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy 2 Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    Leukemia 28:1811-8. 2014
    ....
  44. ncbi request reprint Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide
    A M Vannucchi
    The Bone Marrow Transplant Unit, Division of Haematology, Azienda Ospedaliera Careggi, University of Florence, Florence, Italy
    Br J Haematol 113:479-82. 2001
    ..The simultaneous and selective expansion of CD4+ and CD8+ CMV-specific lymphocytes might be instrumental for more efficient in vivo function of infused CMV-specific lymphocytes...
  45. ncbi request reprint Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
    Paola Guglielmelli
    Department of Hematology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
    Stem Cells 25:165-73. 2007
    ....
  46. doi request reprint Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
    Elisabetta Antonioli
    Department of Hematology, University of Florence, 50134, Florence, Italy
    Haematologica 93:41-8. 2008
    ..The aim of this study was to evaluate possible correlations between JAK2(V617F) mutant allele burden and both clinical presentation and hematologic abnormalities in essential thrombocythemia patients...
  47. pmc The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
    Lisa Pieri
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita degli Studi, Firenze, Italy
    Haematologica 94:1537-45. 2009
    ..The JAK2V617F mutation has been associated with constitutive and enhanced activation of neutrophils, while no information is available concerning other leukocyte subtypes...
  48. ncbi request reprint Anaemia characterises patients with myelofibrosis harbouring Mpl mutation
    Paola Guglielmelli
    Department of Haematology, University of Florence, Florence, Italy
    Br J Haematol 137:244-7. 2007
    ..121 g/l; P = 0.002) and were more likely to require regular transfusional support (P = 0.012). These data indicate that MPL mutation in myelofibrosis characterises patients with more severe anaemic phenotype...
  49. ncbi request reprint Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells
    Cristina Cellai
    Department of Experimental Pathology and Oncology, University of Florence, 50134, Firenze, Italy
    FASEB J 16:733-5. 2002
    ....
  50. ncbi request reprint MicroRNA expression profile in granulocytes from primary myelofibrosis patients
    Paola Guglielmelli
    Department of Hematology, University of Florence, Florence, Italy
    Exp Hematol 35:1708-18. 2007
    ....
  51. ncbi request reprint Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
    Marco Ruggeri
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 111:666-71. 2008
    ..A high proportion of PV and ET surgeries was complicated by vascular occlusion (7.7%) or by a major hemorrhage (7.3%). Prospective investigations analyzing the optimal prophylaxis in these patients are suggested...
  52. ncbi request reprint Constitutive and inducible expression of megakaryocyte-specific genes in Friend erythroleukaemia cells
    A M Vannucchi
    Division of Haematology, Careggi Hospital, Florence, Italy
    Br J Haematol 99:500-8. 1997
    ..According to our results, MELC should be seen as an unique erythro-megakaryocytic model of differentiation, potentially useful for studying molecular events governing lineage commitment as well as some steps of megakaryocytopoiesis...
  53. doi request reprint Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia
    T Barbui
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Leukemia 27:1953-8. 2013
    ..Therefore, this controversy suggests a scientific project, including the community of pathologists and hematologists, for providing sound, objective and reproducible criteria for diagnosing early/prefibrotic PMF. ..
  54. doi request reprint Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN
    Cristina Cellai
    Department of Experimental Pathology and Oncology, University of Florence, 50134 Florence, Italy
    Exp Hematol 37:1176-1185.e21. 2009
    ..This study aimed to investigate the mechanisms of action of WEB-2170, an inverse agonist of platelet-activating factor receptor, capable of inducing apoptosis in human acute myelogenous leukemia (AML) cells...
  55. ncbi request reprint Role of thrombopoietin in mast cell differentiation
    Anna Rita Migliaccio
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Ann N Y Acad Sci 1106:152-74. 2007
    ..Some of the possible implications of this newly described biological activity of thrombopoietin will be discussed...
  56. pmc CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin
    Maria Verrucci
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    J Cell Physiol 225:490-9. 2010
    ..These results indicate that Aplidin effectively alters the natural history of myelofibrosis in Gata1(low) mice and suggest this drug as candidate for clinical evaluation in PMF...
  57. ncbi request reprint Role of GATA-1 in normal and neoplastic hemopoiesis
    Anna Rita Migliaccio
    Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Ann N Y Acad Sci 1044:142-58. 2005
    ..We review our current understanding of the role of GATA-1 in normal and neoplastic hematopoiesis as emerging from these genetic approaches...
  58. pmc Increased differentiation of dermal mast cells in mice lacking the Mpl gene
    Barbara Ghinassi
    Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore Sanita, Rome, Italy
    Stem Cells Dev 18:1081-92. 2009
    ..These results suggest that not only does ligation of thrombopoietin with the Mpl receptor exert an effect at the mast cell restricted progenitor cell level, but also plays an unexpected yet important role in mast cell maturation...
  59. doi request reprint Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis
    Costanza Bogani
    Department of Hematology, University of Florence, 50134 Florence, Italy
    Stem Cells 26:1920-30. 2008
    ..These data point to abnormal methylation of the CXCR4 promoter as a mechanism contributing to constitutive migration of CD34(+) cells in PMF. Disclosure of potential conflicts of interest is found at the end of this article...
  60. doi request reprint Advances in understanding and management of polycythemia vera
    Alessandro M Vannucchi
    Unita Funzionale di Ematologia, Dipartimento di Area Critica, Universita degli Studi di Firenze, Istituto Toscano Tumori, Florence, Italy
    Curr Opin Oncol 22:636-41. 2010
    ..The objective of this report is to review recent advances in the field and discuss the potential of novel therapeutic approaches...
  61. doi request reprint Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    Valerio De Stefano
    Institute of Hematology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 93:372-80. 2008
    ..Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of re-thrombosis and the optimal strategy for prevention of recurrence...
  62. ncbi request reprint Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases
    Alessandro M Vannucchi
    Br J Haematol 132:652-4; author reply 654. 2006
  63. doi request reprint Leukocytosis and risk stratification assessment in essential thrombocythemia
    Alessandra Carobbio
    Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Clin Oncol 26:2732-6. 2008
    ..Established risk factors for thrombosis in essential thrombocythemia (ET) include age and previous vascular events. We aimed to refine this risk stratification by adding baseline leukocytosis...
  64. ncbi request reprint The haematocrit and platelet target in polycythemia vera
    Marcello Di Nisio
    Department of Medicine and Aging, School of Medicine, and Aging Research Centre, Ce S I, Gabriele D Annunzio University Foundation, Chieti Pescara, Italy
    Br J Haematol 136:249-59. 2007
    ..Our findings do not suggest that the range of haematocrit (<55%) and platelet counts (<600 x 10(9)/l) we encountered in our population had an impact on the outcome of PV patients treated by current therapeutic strategies...
  65. ncbi request reprint Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows
    Eva Zetterberg
    Division of Hematology and Center for Inflammation and Hematology Research, Department of Medicine, The Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Haematologica 92:597-604. 2007
    ..Since pericyte abnormalities are described on solid tumor vessels we studied whether vessel morphology and pericyte coverage in bone marrow samples from patients with myelofibrosis differed from that in samples from controls...
  66. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  67. ncbi request reprint Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice
    Lucia Centurione
    Department of Biomorphology, University G D Annunzio, Chieti, Italy
    Blood 104:3573-80. 2004
    ..We suggest that such an increased and pathologic neutrophil emperipolesis may represent one of the mechanisms leading to myelofibrosis by releasing fibrogenic MK cytokines and neutrophil proteases in the microenvironment...
  68. ncbi request reprint The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia
    Vittorio Rosti
    Transplant Research Area, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood Cells Mol Dis 38:280-6. 2007
    ..We studied the expression of the chemokine receptor CXCR4 on circulating CD34+ cells of patients with myelofibrosis with myeloid metaplasia (MMM), and examined its relationship to the severity of disease...
  69. ncbi request reprint A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis
    Alessandro M Vannucchi
    Clinical Biochemistry, Istituto Superiore Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Blood 105:3493-501. 2005
    ..These data indicate that the TPO(high) and GATA-1(low) alterations are linked in an upstream-downstream relationship along a pathobiologic pathway leading to development of myelofibrosis in mice and, possibly, of IM in humans...
  70. doi request reprint Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations
    Alessandro M Vannucchi
    Haematologica 93:972-6. 2008
  71. ncbi request reprint JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    Blood 110:4030-6. 2007
    ..We conclude that JAK2 V617F genotype should be considered in any future risk stratification of patients with PMF...
  72. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  73. ncbi request reprint Robust levels of long-term multilineage reconstitution in the absence of stem cell self-replication in W/Wv mice transplanted with purified stem cells
    Anna Rita Migliaccio
    Laboratorio di Biochimica Clinica, Istituto Superiore di Sanita, 00161 Rome, Italy
    J Hematother Stem Cell Res 12:409-24. 2003
    ..1neg in that few pMRC are included among Sca-1+ cells and that MRC and pMRC are two distinct and separable cell populations...
  74. ncbi request reprint Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance
    Elisabetta Antonioli
    Blood 110:4620-1. 2007
  75. ncbi request reprint Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study
    Alberto Bosi
    Haematologica 87:446-7. 2002
  76. ncbi request reprint Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele
    Lisa Pieri
    Leuk Res 32:516-7. 2008
  77. pmc Thrombopoietin inhibits murine mast cell differentiation
    Fabrizio Martelli
    Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanita, Rome, Italy
    Stem Cells 26:912-9. 2008
    ....